Chest
Pneumococcal Vaccine In Elderly Patients With Copd
Section snippets
Patients
All patients were diagnosed as having either chronic bronchitis or emphysema and were followed on a regular basis at the Kings County Hospital Chest Clinic. Diagnosis was based on a compatible clinical picture, roentgenographic findings, and pulmonary function tests. Persons with asthma were not included in the study. There were 29 patients who were divided in two groups. Group 1 consisted of 17 patients (mean age 70) who did not receive the vaccine and served as control subjects. Group 2
RESULTS
The geometric mean antibody levels for the group 1 and group 2 patients are presented in Table 1. Prevaccination antibody levels derived from normal healthy young adults (age range 20 to 28) are included for comparison purposes (sera supplied by the Bureau of Biologics).
Group 1 patients had geometric mean antibody levels that were slightly but not significantly higher than were seen in healthy nonvaccinated adults (395 ng Ab N/ml vs 217 ng Ab N/ml). Group 2 patients had a total geometric mean
DISCUSSION
Numerous studies have shown that the pneumococcal polyvalent vaccine is capable of inducing antibodies that protect an individual against pneumococcal infection. Most of these studies have been done in relatively healthy young to middle-aged persons.4, 5, 6 There are few data available on antibody responses in the elderly, particularly the elderly with underlying pulmonary disease. Because elderly patients with COPD are a recommended target population for the vaccine, data on the magnitude and
REFERENCES (10)
- et al.
A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines: I. Method for the radioimmunoassay of anticapsular antibodies and a comparison with other techniques
J Immunol Meth
(1980) - Morbidity and Mortality Weekly Report 30(33) 1981...
- et al.
Assessment of the antibody response to pneumococcal vaccine in high-risk populations
Rev Infect Dis
(1981) Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharides: results of a six year study.
Arch Intern Med
(1947)- et al.
Prevention of pneumococcal pneumonia by vaccination
Trans Assoc Am Phys
(1976)
Cited by (19)
Pneumococcal vaccination for patients with COPD: Current practice and future directions
2008, ChestCitation Excerpt :This is an important issue because it is possible that COPD patients may respond differently than the general population, given their ongoing systemic inflammation, chronic colonization of the lower respiratory tract, repeated exacerbations, and frequent use of inhaled and systemic steroids. Studies of biological response have shown that COPD patients can mount antibodies when challenged with pneumococcal vaccine,343536 even when patients are receiving systemic corticosteroids3738 or when the vaccine is given via inhalation.39 Unfortunately, these studies were performed using the earlier generation of ELISAs, limiting the interpretation of their results.
Cost benefits of targeting the Pneumococcal Vaccination Program to the elderly population in Taiwan
2006, American Journal of Infection ControlCitation Excerpt :Of the 2 groups most susceptible to streptococcal pneumonia (ie, children and elderly adults), elderly adults have a comparatively higher death rate. Many studies claim that pneumococcal vaccination can effectively prevent the occurrence of invasive pneumococcal disease (IPD)5-7 and is a cost-effective way to reduce acute exacerbations of COPD.8,9 In Taiwan, the rate of death because of IPD in elderly adults is approximately 42.5%.
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
2017, Cochrane Database of Systematic ReviewsShould patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?
2009, Expert Review of Respiratory Medicine
Assistant Professor of Medicine.
Professor of Microbiology and Immunology.